MOUNTAIN VIEW, CA – November 9, 2010 –
23andMe, Inc., a leading personal genetics company, announced today the closing of its Series C financing. The company raised a total of more than $22 million of funding from a new investor, Johnson & Johnson Development Corporation, and current investors — including New Enterprise Associates and Google Ventures.
“We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make health care research and health care delivery more efficient,” said Anne Wojcicki, chief executive officer of 23andMe.
23andMe is actively recruiting for several key positions within the company. Available positions are listed on the company’s website
This press release does not constitute or form part of, and should not be construed as an offer or an invitation to sell or issue, or the solicitation of any offer to buy or subscribe for, any securities.
23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. The company was named by TIME as a “Genius Company” in 2018, and featured as Fast Company's #2 Most Innovative Health Company in 2018. 23andMe has millions of customers worldwide, with more than 80 percent of customers consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at www.23andMe.com.